ArticleFrontiers in cardiovascular medicine2024
Efficacy and safety of anakinra in radiation-induced acute pericarditis: a case report.
Article in Frontiers in cardiovascular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in the Prevention and Treatment of Radiation Skin Injury: Mechanisms, Pharmacological Interventions, and Applications of Novel Dressings.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute pericarditis represents an inflammatory disease affecting the pericardial layers. In developed countries more than 80% of pericarditis are defined as idiopathic, less frequently they are secondary to other conditions such as infections, rheumatic or systemic inflammatory diseases, cancer, post-cardiac injury syndromes and radiation therapy (RT). Case presentation: We reported a case of a patient with acute pericarditis that occurred a few hours after chest radiation therapy, performed for breast cancer. After the failure of first-line therapy, we introduced anakinra, an anti- interleukin-1 (IL-1) agent, observing an immediate clinical and instrumental response. Conclusions: Our experience highlights the efficacy and safety profile of anakinra in early stages of acute pericarditis with an inflammatory phenotype. To the best of our knowledge, there is no data supporting the use of anakinra in the treatment of RT induced acute pericarditis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.